In another Phase II study, monotherapy with REGN3500/SAR440340 (ST2 blocking mAb) significantly reduced loss of asthma control and improved lung function compared with placebo in adults with moderate-to-severe asthma [8]. The gene discussed is IL1RL1; the disease is asthma.